Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Creative Financial Designs Inc. ADV

Creative Financial Designs Inc. ADV boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 201 shares of the biopharmaceutical company’s stock after purchasing an additional 27 shares during the period. Creative Financial Designs Inc. ADV’s holdings in Regeneron Pharmaceuticals were worth $143,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Glenview Trust co lifted its holdings in shares of Regeneron Pharmaceuticals by 0.8% during the fourth quarter. Glenview Trust co now owns 3,071 shares of the biopharmaceutical company’s stock valued at $2,188,000 after purchasing an additional 25 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in Regeneron Pharmaceuticals by 36.2% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,684 shares of the biopharmaceutical company’s stock valued at $1,912,000 after buying an additional 713 shares in the last quarter. Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $36,000. Choate Investment Advisors increased its position in shares of Regeneron Pharmaceuticals by 7.2% in the fourth quarter. Choate Investment Advisors now owns 551 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 37 shares in the last quarter. Finally, Greykasell Wealth Strategies Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $504,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on REGN. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. TD Cowen dropped their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Finally, Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $662.62 on Friday. The company has a market capitalization of $72.44 billion, a PE ratio of 17.31, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The company’s fifty day moving average price is $690.20 and its 200 day moving average price is $821.82.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the company posted $11.86 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.